5:38 PM
 | 
Oct 05, 2012
 |  BC Extra  |  Company News

Wilex, FDA agree on next trial for Redectane

Wilex AG (Xetra:WL6) reached an agreement with FDA to conduct a second Phase III trial of Redectane that will evaluate the product's diagnostic performance instead of its effect on clinical outcomes. The decision is in line with a July...

Read the full 182 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >